Reata Pharmaceuticals ROE 2024

Reata Pharmaceuticals Aktienanalyse

Šta radi Reata Pharmaceuticals?

Reata Pharmaceuticals Inc is a biopharmaceutical company that was founded in Irving, Texas in 2002. The company develops and markets innovative therapeutics for severe and rare diseases, particularly rare genetic metabolic diseases, neurological diseases, and inflammatory diseases. Reata Pharmaceuticals has a unique business model based on the principle of "platform technology". This means that the company develops various therapeutic approaches based on a patented molecular platform. This platform allows Reata to quickly and efficiently develop new products for different disease areas. An important focus of Reata Pharmaceuticals' activities is the development of therapeutics for rare genetic metabolic diseases. The company has made remarkable progress in this area. In particular, the drug Omaveloxolone, which was developed for the treatment of Friedreich's ataxia, has attracted a lot of attention. This rare disease manifests as progressive spastic paralysis and can eventually lead to death. The drug has shown promising results in a Phase 2 study and is currently in Phase 3 study. Another important area for Reata Pharmaceuticals is inflammatory diseases. The company has developed a product called Bardoxolone Methyl, which is approved for the treatment of chronic kidney disease and pulmonary hypertension. These diseases have a significant impact on the quality of life and life expectancy of patients. Bardoxolone Methyl has shown in clinical studies that it can slow disease progression and significantly improve symptoms. In addition to these two pillars of activity, Reata Pharmaceuticals also has various product candidates for neurological diseases, cancer, and other diseases in the pipeline. The company aims to develop innovative solutions for unmet medical needs and help patients whose needs have not been adequately addressed. The history of Reata Pharmaceuticals is characterized by a successful path as a company with a unique business model. The company aims to play a leading role in the development and marketing of therapeutics for rare and serious diseases. To achieve this, the company has built a strong research and development team and works closely with the academic community. Reata Pharmaceuticals has managed to establish an international network of leading scientists, doctors, and patient organizations. This collaboration is crucial for the successful development and marketing of therapeutics for rare diseases. In summary, Reata Pharmaceuticals Inc is an innovative biopharmaceutical company that uses a unique platform technology for the development of therapeutics for rare and severe diseases. The company has made remarkable progress in the development of therapeutics for rare genetic metabolic diseases and inflammatory diseases and is working on additional products for neurological diseases, cancer, and other diseases. Reata Pharmaceuticals aims to play a leading role in the industry and help patients whose needs have not been adequately addressed. Reata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE у детаљу

Razjašnjenje povrata na sopstveni kapital (ROE) kompanije Reata Pharmaceuticals

Povraćaj na sopstveni kapital (ROE) kompanije Reata Pharmaceuticals je osnovni pokazatelj koji ocenjuje profitabilnost kompanije u odnosu na sopstveni kapital. ROE, izračunat deljenjem neto dobiti sa sopstvenim kapitalom akcionara, ilustruje efikasnost kompanije u ostvarivanju profita iz investicija akcionara. Viši ROE označava povećanu efikasnost i profitabilnost.

Poređenje iz godine u godinu

Analiza ROE kompanije Reata Pharmaceuticals iz godine u godinu pomaže u praćenju trendova profitabilnosti i finansijskih performansi. Rastući ROE ukazuje na povećanu profitabilnost i stvaranje vrednosti za akcionare, dok opadajući ROE može ukazivati na probleme u stvaranju dobiti ili upravljanju sopstvenim kapitalom.

Uticaj na investicije

ROE kompanije Reata Pharmaceuticals je ključan za investitore koji ocenjuju profitabilnost, efikasnost i privlačnost kompanije kao investicije. Robusni ROE ukazuje na sposobnost kompanije da pretvori investicije sopstvenog kapitala u profit, čime povećava svoju privlačnost potencijalnim i sadašnjim investitorima.

Interpretacija fluktuacija ROE

Promene u ROE kompanije Reata Pharmaceuticals mogu proizaći iz fluktuacija neto dobiti, sopstvenog kapitala ili oboje. Ove fluktuacije se analiziraju sa ciljem procene efikasnosti menadžmenta, finansijskih strategija, kao i povezanih rizika i mogućnosti, te pomažu investitorima u donošenju obrazloženih odluka.

Često postavljana pitanja o Reata Pharmaceuticals akciji

Koliki je ROE (Return on Equity) kompanije Reata Pharmaceuticals ove godine?

ROE kompanije Reata Pharmaceuticals u ovoj godini iznosi 4,75 undefined.

Kako se ROE (Return on Equity) kompanije Reata Pharmaceuticals razvio u poređenju sa prethodnom godinom?

ROE kompanije Reata Pharmaceuticals se u poređenju sa prošlom godinom promenio za -396,93% pao.

Kakav uticaj visoki ROE (povraćaj na kapital) ima na investitore Reata Pharmaceuticals?

Visok ROE pokazuje da Reata Pharmaceuticals postiže dobar povraćaj kapitala i da je uspešan u monetizaciji svojih investicija. Ovo je za investitore pozitivan indikator.

Koji uticaj ima nizak ROE (Povraćaj na kapital) na investitore Reata Pharmaceuticals?

Nizak ROE može ukazivati na to da Reata Pharmaceuticals ima poteškoće u uspešnom monetizovanju svojih investicija i može biti negativan signal za investitore.

Kako promena ROE (Return on Equity) od Reata Pharmaceuticals utiče na preduzeće?

Promena ROE (povraćaja na kapital) od Reata Pharmaceuticals može biti indikator finansijske performanse kompanije i pokazati koliko je uspešna u odnosu na druge kompanije u istoj industriji.

Kako se izračunava ROE (Povraćaj na sopstveni kapital) od Reata Pharmaceuticals?

ROE (Return on Equity) se izračunava tako što se dobit preduzeća podeli sa ukupnim kapitalom. Formula glasi: ROE = Dobit / Ukupni kapital.

Koji faktori utiču na ROE (Return on Equity) kompanije Reata Pharmaceuticals?

Neki faktori koji mogu uticati na ROE (Return on Equity) kompanije Reata Pharmaceuticals uključuju, između ostalih, efikasnost u korišćenju sopstvenog kapitala, profitabilnost preduzeća i strukturu finansiranja.

Koje strateške mere može preduzeti da poboljša ROE (povrat na kapital)?

Da bi poboljšao ROE (Return on Equity), može preduzeti različite mere kao što su smanjenje troškova, povećanje prihoda, poboljšanje efikasnosti korišćenja kapitala i promene u strukturi finansiranja. Važno je da kompanija izvrši temeljnu proveru svoje finansijske situacije kako bi odredila najbolje strateške mere za poboljšanje ROE (Return on Equity).

Kolika je dividenda koju isplaćuje Reata Pharmaceuticals?

U poslednjih 12 meseci, Reata Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Reata Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Reata Pharmaceuticals?

Dividendski prinos od Reata Pharmaceuticals trenutno iznosi .

Kada Reata Pharmaceuticals isplaćuje dividendu?

Reata Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Reata Pharmaceuticals?

Reata Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Reata Pharmaceuticals?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Reata Pharmaceuticals?

Reata Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Reata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Reata Pharmaceuticals od 10. 5. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 10. 5. 2024..

Kada je Reata Pharmaceuticals poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 10. 5. 2024..

Kolika je bila dividenda od Reata Pharmaceuticals u godini 2023?

U godini 2023 kompanija Reata Pharmaceuticals je isplatila 0 USD kao dividende.

U kojoj valuti Reata Pharmaceuticals isplaćuje dividendu?

Dividende od Reata Pharmaceuticals se isplaćuju u USD.